Financial News Feed

Stronger Sell Today ACOR ranks #4075 as SELL CANDIDATE. Weaker Sell
Today ACOR ranks #4075 as SELL CANDIDATE.

ACOR stock Acorda Therapeutics

ACOR stock
Acorda Therapeutics

In a report released today, Jay Olson from Oppenheimer maintained a Hold rating on Acorda Therapeutics (ACOR), with a price target of $15. ... The post Oppenheimer Keeps a Hold Rating on Acorda Therap...

Read more

Acorda Therapeutics (ACOR)’s indicators and moving averages are pointing to a potential reversal at the Chikou line has ducked under the Tenkan, indicating that a reversal of price might be nearing....

Read more

Both CASI Pharmaceuticals Inc. (NASDAQ:CASI) and Acorda Therapeutics Inc. (NASDAQ:ACOR) are each other’s competitor in the Biotechnology industry. Thus the...

Read more

In taking a look at some key indicators for Acorda Therapeutics, Inc. (NasdaqGS:ACOR), we note that the current Book to Market value for the firm is at 0.978505. The Book to Market or BTM is calculate...

Read more

BidaskClub cut shares of Acorda Therapeutics (NASDAQ:ACOR) from a hold rating to a sell rating in a report released on Friday morning. ACOR has been the subject of several other reports. Raymond James...

Read more

Since Sutro Biopharma Inc. (NASDAQ:STRO) and Acorda Therapeutics Inc. (NASDAQ:ACOR) are part of the Biotechnology industry, they are influenced by compare. The...

Read more

Equities research analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to announce earnings of ($0.81) per share for the current quarter, according to Zacks. Three analysts have made estimates for Ac...

Read more

Equities analysts forecast that Acorda Therapeutics Inc (NASDAQ:ACOR) will announce $36.57 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provide...

Read more

Stone Run Capital Llc decreased Becton Dickinson & Co (BDX) stake by 23.15% reported in 2018Q4 SEC filing. Stone Run Capital Llc sold 8,852 shares as Becton Acorda Therapeutics, Inc. (NASDAQ:ACOR) Rat...

Read more

Equities analysts forecast that Acorda Therapeutics Inc (NASDAQ:ACOR) will announce $36.57 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estim...

Read more

The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Acorda The...

Read more

Acorda Therapeutics, Inc. (NasdaqGS:ACOR) has a current EV or Enterprise Value of 721588. The EV displays how the market assigns value to a company as a whole. EV is generally a modification of market...

Read more

Acorda Therapeutics (ACOR) has ended the week in the red, yielding negative results for the shares at they ticked -10.25%. In taking a look at recent performance, we can see that shares have moved -1....

Read more

We are comparing Acorda Therapeutics Inc. (NASDAQ:ACOR) and Pluristem Therapeutics Inc. (NASDAQ:PSTI) on their risk, analyst recommendations, profitability,...

Read more

OncoCyte Corporation (NYSEAMERICAN:OCX) and Acorda Therapeutics Inc. (NASDAQ:ACOR) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional owne...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank